by | Jun 7, 2024 | Publications
Cancer Med. 2024 Jun;13(11):e7194. doi: 10.1002/cam4.7194. ABSTRACT BACKGROUND: Myc rearrangement (Myc-R) is a controversial factor linked to adverse outcomes in newly diagnosed multiple myeloma (NDMM). AIMS: This study aimed to evaluate the impact of Myc-R on the...
by | Jun 7, 2024 | Publications
Cureus. 2024 May 7;16(5):e59781. doi: 10.7759/cureus.59781. eCollection 2024 May. ABSTRACT Multiple myeloma (MM) remains an incurable hematologic cancer leading to damage to the bone marrow that causes destructive bone lesions in addition to many other effects. I am a...
by | Jun 7, 2024 | Publications
Ann Med Surg (Lond). 2024 Apr 24;86(6):3721-3723. doi: 10.1097/MS9.0000000000002088. eCollection 2024 Jun. ABSTRACT INTRODUCTION: Multiple myeloma (MM) is a malignant plasma cell proliferation producing large numbers of monoclonal immunoglobulins. Typical MM symptoms...
by | Jun 7, 2024 | Publications
Front Immunol. 2024 May 23;15:1377546. doi: 10.3389/fimmu.2024.1377546. eCollection 2024. ABSTRACT INTRODUCTION: Multiple Myeloma (MM), a prevalent hematological malignancy, poses significant treatment challenges due to varied patient responses and toxicities to...
by | Jun 7, 2024 | Publications
Chin Med J (Engl). 2024 Jun 6. doi: 10.1097/CM9.0000000000003116. Online ahead of print. ABSTRACT BACKGROUND: Although significant advances have been made in the treatment of multiple myeloma (MM), leading to unprecedented response and survival rates among patients,...
by | Jun 7, 2024 | Publications
J Hematol Oncol. 2024 Jun 6;17(1):42. doi: 10.1186/s13045-024-01555-4. ABSTRACT Idecabtagene vicleucel (Ide-cel) has demonstrated excellent efficacy and durable responses in patients with relapsed/refractory multiple myeloma (RRMM). However, the outcomes with ide-cel...
